

Subject: [gbird] FW: 2017 ABSA Webinar: Gene Editing, CRISPR, and Gene Drives

From: Heath Packard <heath.packard@islandconservation.org>

Date: 5/10/2017 1:39 PM

To: "gbird@lists.ncsu.edu (gbird@lists.ncsu.edu)" <gbird@lists.ncsu.edu>

Hi, all. I was just made aware of this and thought you might be interested in how it is presented...

Begin forwarded message:

From: ABSA International <ed@absaoffice.org>

Date: May 10, 2017 at 9:02:13 AM EDT

To:

Subject: 2017 ABSA Webinar: Gene Editing, CRISPR, and Gene Drives

Reply-To: ed@absaoffice.org



ABSA
INTERNATIONAL
The Association for Biosafety and Biosecurity

**Gene Editing, CRISPR, and Gene Drives:
Biosafety Considerations**

A distance learning opportunity

July 13, 2017

12:30 - 2:30pm (CDT)

Gene Editing, CRISPR, and Gene Drives: Biosafety Considerations is intended to provide an overview of biosafety considerations surrounding the use of gene editing tools, such as TALENS, zinc fingers, and CRISPR/Cas9 in research laboratories. The webinar will cover an introduction to these editing tools, current biosafety considerations and risk assessment strategies, and regulatory considerations. Additionally, this course will introduce the topic of gene drives: when is a gene drive created, what are the risks and when a consultation with a gene drive expert is needed.

This webinar will be a 2-hour webinar session on Thursday, July 13, 2017 at 12:30pm CDT. For the webinar, you should plan on logging in at 12:15 pm (CDT) on July 13. You are required to attend the webinar session, complete the pre and post assessments, and evaluation in order to earn P.A.C.E.® Contact Hours*. The link in the invitation will be unique to the user and cannot be shared.

Upon completion of this webinar, participants will be able to:

- Restate the mechanisms of how TALENS, zinc fingers and the CRISPR/Cas9 system modify DNA
- Determine how commonly used applications of CRISPR/Cas9 are regulated, with a focus on the NIH Guidelines
- Outline things to consider when performing a risk assessment of CRISPR/Cas9 experiments
- Describe what a gene drive is and how to proceed with a risk assessment if experiments may create a gene drive

The webinar will be presented by:

Richard DiTullio, PhD

Vanderbilt University
Nashville, TN

Kevin Esvelt, PhD

Massachusetts Institute of Technology
Cambridge, MA

Additional information and registration can be found at

<https://absa.org/online-education/>



ABSA International

info@absa.org

<https://www.absa.org/>

Toll-Free: **[866-425-1385](tel:866-425-1385)**

[847-949-1517](tel:847-949-1517)

See what's happening on our social sites



American Biological Safety Association,
1200 Allanson Road, Mundelein, IL 60060

[SafeUnsubscribe™ dobrocht@umd.edu](mailto:SafeUnsubscribe™_dobrocht@umd.edu)

[Forward this email](#) | [About our service provider](#)

Sent by ed@absaoffice.org in collaboration with

Constant Contact 

[Try it free today](#)